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Abstract
Background: The present commonly used five-year survival rates are not adequate to represent the statistical
cure. In the present study, we established the minimum number of years required for follow-up to estimate
statistical cure rate, by using a lognormal distribution of the survival time of those who died of their cancer. We
introduced the term, threshold year, the follow-up time for patients dying from the specific cancer covers most
of the survival data, leaving less than 2.25% uncovered. This is close enough to cure from that specific cancer.
Methods: Data from the Surveillance, Epidemiology and End Results (SEER) database were tested if the survival
times of cancer patients who died of their disease followed the lognormal distribution using a minimum chi-square
method. Patients diagnosed from 1973–1992 in the registries of Connecticut and Detroit were chosen so that a
maximum of 27 years was allowed for follow-up to 1999. A total of 49 specific organ sites were tested. The
parameters of those lognormal distributions were found for each cancer site. The cancer-specific survival rates
at the threshold years were compared with the longest available Kaplan-Meier survival estimates.
Results: The characteristics of the cancer-specific survival times of cancer patients who died of their disease from
42 cancer sites out of 49 sites were verified to follow different lognormal distributions. The threshold years
validated for statistical cure varied for different cancer sites, from 2.6 years for pancreas cancer to 25.2 years for
cancer of salivary gland. At the threshold year, the statistical cure rates estimated for 40 cancer sites were found
to match the actuarial long-term survival rates estimated by the Kaplan-Meier method within six percentage
points. For two cancer sites: breast and thyroid, the threshold years were so long that the cancer-specific survival
rates could yet not be obtained because the SEER data do not provide sufficiently long follow-up.
Conclusion: The present study suggests a certain threshold year is required to wait before the statistical cure
rate can be estimated for each cancer site. For some cancers, such as breast and thyroid, the 5- or 10-year survival
rates inadequately reflect statistical cure rates, and highlight the need for long-term follow-up of these patients.
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Background
The normal distribution is often used to describe the ran-
dom variation of data in many scientific disciplines. How-
ever some distributions are skewed with low mean values
and large variance. The distributions may be exclusively
positive, such as the duration of survival of cancer patients
with chronic leukemias [1], the incubation time of infec-
tious diseases [2], and the abundance of biological species
[3], etc. These skewed distributions often fit the lognor-
mal distribution [4-7]. A lognormal distribution is one
with random variables whose logarithms follow a normal
distribution. The lognormal survival time of cancer
patients, who died of their disease, has been tested and
applied for various anatomic sites [8-21].
The term survival rate is used commonly, yet it is inaccu-
rate. Five- and ten-year survival rates are commonly used
in the literature. Kaplan-Meier or life-table (actuarial)
methods estimate the proportion (or fraction) of survi-
vors. In this study, the term "survival rate" means "sur-
vival fraction" expressed in percentage, and the term "cure
rate" means "cure fraction" expressed in percentage, to be
proper.
It is difficult to know the statistical cure rate, which is an
estimation based on statistical models [11,15], especially
for slowly proliferating tumors. Because of this limitation,
oncologists usually discuss survival in terms of 5-year or
10-year survival rates. In certain rapidly growing tumors,
the cancer-specific survival rate [22] reaches a plateau
within 5–10 years and approaches the statistical cure rate,
which is the survival rate observed when no more risk of
death from the disease. In the Kaplan-Meier method [23],
a person with residual cancer but who died of reasons
other than the specific cancer is censored for cancer-spe-
cific survival. In the present study we applied the analysis
on the cancer-specific survival rates. The statistical cure
was reached at the plateau of the Kaplan-Meier plot of the
cancer-specific survival rate. For some fast proliferating
cancers, such as pancreatic and stomach cancers, the pla-
teau appears within 10 years. However for some slow pro-
liferating cancers, such as thyroid and early breast cancers,
the plateau does not appear even after decades. Hence the
present commonly used five-year survival rates are not
adequate to represent the statistical cure rate.
In the present study, we established the minimum
number of years required for follow-up in order to esti-
mate the statistical cure rate, by using a lognormal distri-
bution of the survival time of those who died of their
cancer by applying the result derived by Limpert et al.[24]
This minimum number of years required for follow-up
was defined as the threshold year by µ* × (σ *)2 where µ*
is the median and σ * is the multiplicative standard devia-
tion of a lognormal distribution (see Additional file 1 :
Appendix). The follow-up time for patients dying from
the specific cancer covers most of the survival data, leaving
less than 2.25% uncovered. This is close enough to cure
from that specific cancer.
Methods
Data sources
We analysed the 1973–1999 Database of the Surveillance,
Epidemiology, and End Results (SEER) Program [25] of
the United States National Cancer Institute. Data from
registries of Connecticut and Detroit were used in this
study and results were compared with the SEER-9 regis-
tries. The cancer sites were chosen according to the SEER
codes. Primary site, vital status, cause of death, and sur-
vival time information were used. Those patients with
unknown or zero survival time and unknown cause of
death were excluded.
To test for lognormality of survival time of cancer patients
who died of cancer-specific disease, patients diagnosed
from 1973–1992 in the registries of Connecticut and
Detroit were chosen so that a maximum of 27 years was
allowed for follow-up to 1999. A total of 49 specific can-
cer sites were tested. For prostate, salivary gland, breast,
and thyroid cancer, patients diagnosed from 1973–1977
were chosen to allow a long enough time for follow-up to
1999. For cancer sites with high frequencies of older
patients, such as lung and bronchus, colon, prostate, and
breast, younger patient ages less than 60 were chosen,
because elderly patients are more likely to die of intercur-
rent diseases and so affect the distribution of cancer-spe-
cific deaths versus other deaths.
As an illustration for special cohorts of interest, breast can-
cer was further analyzed based on accepted prognostic fac-
tors such as stage, histologic type and tumor grade, to
show that the threshold years were different for different
cohorts of interest.
Statistical analysis
The survival times of the cancer patients who died of their
disease were tested for goodness of fit for lognormality
using a minimum chi-square method. The class intervals
were in the powers of 2 in months of the survival time,
such as 0–2, >2–4, >4–8, >8–16, and so on. The values of
M, mean of the log (survival time), and S, standard devia-
tion of the log (survival time), were varied in the tests so
that a minimum chi-square value was obtained. The null
hypothesis states that there is no difference between the
observed data distribution and the lognormal distribu-
tion. It is rejected if P < 0.05. The values of M and S were
obtained when the chi-square value reached a minimum.
Let τ  be the threshold year at which statistical cure rate can
be estimated, then the cancer-specific survival rate can beBMC Cancer 2005, 5:48 http://www.biomedcentral.com/1471-2407/5/48
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obtained by Kaplan-Meier method with follow-up time
equal to τ . This cancer-specific survival rate at time τ  was
an estimation of the statistical cure rate of the disease. It
was compared with the long-term cancer-specific rate cal-
culated using Kaplan-Meier method with the actual long-
term data available up to 1999 (Figures 1 and 2).
Results
Lognormality
The present study verified that, for 42 specific organ sites
out of 49 cancer sites in the SEER database, the survival
time of cancer patients who died of their disease followed
different lognormal distributions approximately. For the
Table 1: List of cancer sites following lognormal distribution and their S (standard deviation of the log-survival), multiplicative 
standard deviation, M (mean of the log-survival), and median values at minimum chi-square with maximum P-value
Site S SD* M† Median‡ Pt. No. P-value
Pancreas 0.45 2.82 0.60 3.98 11185 0.57
Gallbladder 0.54 3.47 0.52 3.31 1196 0.60
Liver 0.62 4.17 0.41 2.57 1701 0.22
Esophagus 0.44 2.75 0.80 6.31 4915 0.35
Hypopharynx 0.41 2.57 0.96 9.12 298 0.57
Stomach 0.51 3.24 0.82 6.61 8608 0.13
Intrahepatic Bile Duct 0.61 4.07 0.63 4.27 105 0.50
Tonsil 0.46 2.88 1.02 10.47 137 0.70
Ureter 0.41 2.57 1.15 14.13 125 0.65
Tongue 0.47 2.95 1.05 11.22 684 0.44
Brain 0.64 4.37 0.74 5.50 2870 0.16
Lung & Bronchus (age<60) 0.63 4.27 0.78 6.03 18913 0.62
Floor of Mouth 0.42 2.63 1.20 15.85 126 0.95
Small Intestine 0.55 3.55 0.99 9.77 364 0.44
Ovary 0.48 3.02 1.13 13.49 4533 0.58
Vagina 0.49 3.09 1.13 13.49 108 0.30
Cecum 0.52 3.31 1.08 12.02 2702 0.16
Nasopharynx 0.46 2.88 1.19 15.49 151 0.90
Corpus Uteri 0.45 2.82 1.22 16.60 1446 0.73
Cervix Uteri 0.46 2.88 1.21 16.22 2256 0.72
Large Intestine, NOS 0.61 4.07 0.91 8.13 622 0.72
Splenic Flexure 0.48 3.02 1.19 15.49 506 0.43
Other Nervous System# 0.50 3.16 1.14 13.80 31 0.88
Colon (age<60) 0.45 2.82 1.26 18.20 2868 0.49
Hepatic Flexure 0.55 3.55 1.06 11.48 455 0.42
Penis 0.61 4.07 0.97 9.33 107 0.39
Uterus, NOS 0.62 4.17 0.96 9.12 81 0.40
Anus, Anal Canal & Anorectum 0.44 2.75 1.33 21.38 129 0.87
Nasal Cavity, Middle Ear & Accessory Sinuses 0.52 3.31 1.20 15.85 109 0.58
Soft Tissue (with heart) 0.50 3.16 1.25 17.78 445 0.52
Bones & Joints 0.54 3.47 1.21 16.22 208 0.78
Larynx 0.50 3.16 1.30 19.95 1752 0.43
Skin Melanomas 0.42 2.63 1.49 30.90 1744 0.24
Appendix 0.48 3.02 1.40 25.12 49 0.64
Vulva 0.62 4.17 1.15 14.13 235 0.11
Retroperitoneum 0.69 4.90 1.00 10.00 100 0.59
Pleura 0.75 5.62 0.90 7.94 47 0.47
Eye & Orbit 0.43 2.69 1.59 38.90 106 0.88
Prostate (age<60, 1973–77) 0.40 2.51 1.67 46.77 413 0.44
Salivary Gland (1973–77) 0.58 3.80 1.33 21.38 65 0.81
Breast (age<60, 1973–77) 0.47 2.95 1.71 51.29 4047 0.23
Thyroid (1973–77) 0.97 9.33 1.28 19.05 123 0.15
The order of organ sites follows Table 2 in ascending order of the threshold years;
SD* Mutiplicative standard deviation of the lognormal distribution;
† M values in log-months;
‡ Median in months;
Pt. No. denotes the number of patients died of the specific cancer;
# Nervous system other than brain.BMC Cancer 2005, 5:48 http://www.biomedcentral.com/1471-2407/5/48
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cancer sites with cancer-specific survival time following
lognormal distribution, the number of patients and val-
ues of S, multiplicative standard deviation, M, median
and P at minimum chi-square are listed in Table 1. All the
P-values in Table 1 are above 0.10.
The seven specific organ sites failed in the test for lognor-
mality were: lip, oropharynx, rectosigmoid junction, rec-
tum, testis, urinary bladder, and kidney & renal pelvis.
Table 2: List of cancer sites following lognormal distribution in ascending order of τ  (the threshold year for estimation of statistical 
cure rate)
Site τ  (yr.) CSSR (τ ) CSSR (LT) Diff. Pt. No.
Pancreas 2.6 7.1 3.3 3.8 14926
Gallbladder 3.3 24.6 20.1 4.5 2123
Liver 3.7 13.7 10.6 3.1 3244
Esophagus 3.9 14.5 9.9 4.6 7021
Hypopharynx 5.1 66.9 62.2 4.7 1869
Stomach 5.8 27.3 22.3 5.0 15310
Intrahepatic Bile Duct 5.9 23.7 20.3 3.4 327
Tonsil 7.4 82.5 79.8 2.7 1137
Ureter 7.8 86.2 85.3 0.9 1122
Tongue 8.0 61.0 56.1 4.9 2264
Brain 8.6 24.4 22.0 2.4 5019
Lung & Bronchus (age<60) 9.0 17.0 11.2 5.8 24408
Floor of Mouth 9.3 80.3 75.1 5.2 1430
Small Intestine 10.3 65.7 65.2 0.5 1633
Ovary 10.4 38.0 34.9 3.1 8400
Vagina 10.6 81.0 81.0 0 618
Cecum 10.8 53.4 48.5 4.9 6766
Nasopharynx 10.8 55.4 49.5 5.9 456
Corpus Uteri 11.1 99.0 98.3 0.7 14894
Cervix Uteri 11.2 69.7 68.2 1.6 8166
Large Intestine, NOS 11.2 41.5 37.8 3.7 1466
Splenic Flexure 11.6 49.5 47.2 2.3 1223
Other Nervous System# 11.7 85.8 83.6 2.1 293
Colon (age<60) 12.2 60.1 57.1 3.0 7556
Hepatic Flexure 12.3 52.0 49.2 2.8 1184
Penis 13.0 83.7 83.7 0 766
Uterus, NOS 13.4 70.5 70.5 0 423
Anus, Anal Canal & Anorectum 13.5 85.3 85.3 0 1254
Nasal Cavity, Middle Ear & Accessory Sinuses 14.6 65.2 65.2 0 449
Soft Tissue (with heart) 15.1 69.3 66.1 3.2 1938
Bones & Joints 16.2 63.8 63.3 0.5 728
Larynx 16.8 73.7 68.6 5.1 8899
Skin Melanomas 18.2 77.8 75.8 2.0 10905
Appendix 19.7 66.8 66.8 0 199
Vulva 20.2 84.5 83.6 0.7 1931
Retroperitoneum 20.2 74.3 74.3 0 681
Pleura 21.2 72.1 72.1 0 376
Eye & Orbit 23.8 84.4 82.7 1.7 641
Prostate (age<60, 1973–77) 24.6 36.7 33.9 2.8 809
Salivary Gland (1973–77) 25.2 73.5 73.5 0 309
Breast (age<60, 1973–77) 36.2 xxx 52.5 xxx 9549
Thyroid (1973–77) 134.1 xxx 88.7 xxx 1259
CSSR (τ ) denotes cancer-specific survival rate at τ  year in percent, calculated by Kaplan-Meier method;
CSSR (LT) denotes long-term cancer-specific survival rate in percent, calculated by Kaplan-Meier method up to 1999;
Diff. denotes difference between CSSR (τ ) and LT CSSR in percentage point;
Pt. No. denotes number of all patients, alive or dead, with or without disease;
NOS denotes not otherwise specified;
# Nervous system other than brain;
xxx denotes data not available as at 1999.BMC Cancer 2005, 5:48 http://www.biomedcentral.com/1471-2407/5/48
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Estimation of statistical cure rate
The threshold years validated for statistical cure were
found to range from 2.6 years for pancreatic cancer to 25.2
years for cancer of salivary gland. For these 40 cancer sites
with survival time followed a lognormal distribution,
their cancer-specific survival rates were obtained by Kap-
lan-Meier method at the threshold year, and they were
compared with their corresponding long-term survival
rates with follow-up to 1999. Out of the 42 cancer sites
with survival time followed a lognormal distribution
approximately, the statistical cure rates for 40 cancer sites
were found to match the actuarial long-term survival rates
estimated by the Kaplan-Meier method within six percent-
age points, at threshold year. For the two remaining can-
cer sites: breast and thyroid, the values of their threshold
years were so long that the cancer-specific survival rates
could not be obtained because the SEER data up to 1999
do not provide sufficient long-term follow-up. Table 2
shows the comparison of the cancer-specific survival rates
at τ  year and at long-term follow-up.
Breast cancer was further analyzed according to accepted
prognostic factors. The corresponding threshold years
according to stages in the SEER classification: localized
(age < 50), regional (age < 50) and distant were 30.8, 27.9,
and 13.1 years respectively. For histologic types: medul-
lary, ductal combined with adenocarcinoma not other-
wise specified (NOS), and lobular, the threshold years
were 17.0, 30.6, and 46.0 years respectively. The threshold
years according to breast tumor grades were 39.8, 26.3,
and 20.7 years for Grades I, II, and III+IV respectively. The
breast cancer-specific survival rates at their threshold years
were 9% for distant stage, 68% for medullary histology,
and 40% for Grades III+IV breast cancer. These three sur-
vival rates were only one percentage point higher when
compared with the available long-term actuarial survival
rates. For regional stage and Grade II breast cancer, their
threshold years were 27.9 and 26.3 respectively. It can be
predicted that a few more years of follow-up are needed to
see the plateau and their statistical cure rates are close to
39% and 47% respectively. The most recently available
SEER database is now up to end of 2001. With 2 addi-
tional years of follow-up from the end of 1999, the cancer-
specific survival rates were 39% and 44% respectively. For
those with τ  values longer than 27 years, the cancer-spe-
cific survival rates could not be obtained because the SEER
data to date do not provide sufficiently long enough fol-
low-up time.
Discussion
The cancer-specific survival has not included the deaths
due to other causes. The cancer-specific rates also depend
on the reliability of the assignment of the cause of death.
Generally, cancer-specific death rates underestimate the
mortality associated with a diagnosis of the specific
cancer, because some patients died of other causes[26].
SEER is a set of geographically defined, population-based,
central cancer registries in the United States, operated by
local non-profit organizations under contract to the
National Cancer Institute (NCI). Registry data are submit-
ted electronically to the NCI on a biannual basis, and the
NCI makes the data available for analysis. The SEER Pro-
gram is considered the standard for quality among cancer
registries around the world. Quality control has been an
integral part of SEER since its inception. Every year, stud-
ies are conducted in SEER areas to evaluate the quality and
completeness of the data being reported.
Gamel and Vogel [27] have compared the advantage of
lognormal distribution over other distributions such as
Weibull and log logit.
The 1973–1992 data were used so that the data were not
out-dated. For a lognormal distribution of the survival
time of those patients died of the specific cancer, there
were only a very small proportion dying at the tail of fol-
low-up (Figure 1), so it would not cause much change to
the lognormal distribution, even with only 7 years of fol-
low-up to 1999 at the tail. For those cancer sites with
threshold years longer than 24 years, the 1973–1977 data
were used so as to allow a long enough time for follow-up
to 1999.
For 42 sites in the SEER database, the survival times of
cancer patients who died of their disease followed differ-
ent lognormal distributions. For 40 cancer sites, the ulti-
mate cure rate can be roughly estimated from the cancer-
specific survival rates at τ  years. These are the required
minimum number of follow-up years for the estimation
of the cure rates. They are different for different cancer
sites. For pancreatic cancer, with its typically short natural
history, the cure rate can be estimated after only 2.6 years.
For cancers with a longer natural history, longer follow-up
periods are required; such as breast (36.2 years). These
long periods are cancer-specific survival times and in real-
ity patients may die from intercurrent non-cancer causes
before τ  years. For thyroid cancer, the estimated threshold
year was 134.1 years. It seems that for some slow prolifer-
ating cancer types, the cure can never be estimated due to
the limit of human lifetime.
We also find that the required minimum number of years
of follow-up, τ , is independent of cure rate (correlation
coefficient of determination, R2 = 0.10). Even for cancer
sites where the cure rates were >50%, the required follow-
up time τ  could be less than 10 years. On the other hand,
for other cancer sites, the cure rates could be < 50%, and
the required follow-up time were >10 years. It shows that
5- or 10-year survival rates are inadequate to reflect the
statistical cure rates.BMC Cancer 2005, 5:48 http://www.biomedcentral.com/1471-2407/5/48
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If there are more patients dying due to other causes than
dying due to the specific cancer, then the cause specific
survival time distribution will not be lognormal. Hence it
is not expected that all cancer-specific survival time distri-
butions will follow lognormal distributions.
According to the bell-shaped property of a normal distri-
bution, from 0 to τ  year covers 97.75% of the lognormally
distributed survival time of those cancer patients who
died from their specific cancer. The cancer-specific sur-
vival rates estimated at τ  years, generally, slightly overesti-
mate the long-term cure rates compared to the Kaplan-
Meier method, but the differences are reasonably small,
by less than six percentage points as verified empirically.
We still need to follow the patients to τ  year to know the
actual value of the estimated cure rates.
For both rapidly and slowly proliferating cancers, we have
shown that the statistical cure rates can be estimated
before a stable plateau is reached in the Kaplan-Meier sur-
vival curve. It may take decades to see a stable plateau,
during this waiting time many patients might be lost to
follow-up or die of intercurrent diseases.
Gamel and Vogel [28] used cause-specific survival and rel-
ative survival to determine actuarial survival in breast can-
The survival time for cancer patients who died of their disease Figure 1
The survival time for cancer patients who died of their disease. The single arrow shows the location of the threshold year (τ ). 
This diagram uses stomach cancer data as an example.
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cer patients from the SEER database. They found that
there was only minimal deviation between the two sur-
vival methods.
Ries et al. [29] reported up to 20-year relative survival rates
(RSR) from 9 registries of the SEER database. For cancers
of pancreas, esophagus and stomach, the RSR were
slightly decreased after five years since diagnosis. These
are consistent with the threshold years of the present
study varying from 2.6 years for pancreas, to 3.9 years for
esophagus, and to 5.8 years for stomach. Dickman et al.
[30] reported similar results with 10-year RSR for the
Finnish Cancer Registry. Talback et al.[31] also showed
the similar results on two RSR graphs up to 30 years for
pancreas and stomach for the Swedish Cancer Registry.
The threshold year of statistical cure for ovarian cancer
was 10.4 years. It was consistent with the results of Ries et
al. and Dickman et al. up to 10 years. After 10 years, there
was only a slight decrease in RSR as reported by Ries et al.
Talback et al. showed the same results on a RSR graph for
ovarian cancer. Their results were also consistent with the
present study for the cancer sites of lung, colon and skin
melanomas, which have threshold years of 9.0, 12.2 and
18.2 years respectively. These consistencies show that the
results obtained from two SEER registries in the present
Cancer-specific survival rate of cancer patients who died of their disease calculated by Kaplan-Meier method Figure 2
Cancer-specific survival rate of cancer patients who died of their disease calculated by Kaplan-Meier method. Note the small 
difference between the cancer-specific survival rate at τ  year as compared to the long-term survival rate. The single arrow 
shows the location of the threshold year (τ ). The pair of opposing arrows at the long-term follow-up shows that the difference 
between the estimated and actual cancer-specific rate is small, less than six percentage points. The survival time for cancer 
patients who died of their disease for stomach cancer is shown as an example.
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study are similar to those from 9 registries and from the
Finnish and Swedish Cancer Registries.
For prostate cancer, the threshold year for statistical cure
was 24.6 years. The RSR graph started to level after 24
years since diagnosis in the article of Talback et al.
For breast cancer, the threshold year was 36.2 years, RSR
leveling was not seen even 30 years after diagnosis in the
article of Talback et al. Leveling of RSR in breast cancer was
also not seen in two separate studies by Schairer et al. [32]
and Brenner and Hakulinen [33]. Kerr et al. [34] reported
that the ratio of observed to expected mortality remained
significantly greater than unity for at least 25 years follow-
ing diagnosis and treatment, indicating a failure to
demonstrate cure of the disease in a statistical sense for a
median of 32 years of follow-up.
Conclusion
The present study suggests a certain threshold year is
required to wait before the statistical cure rate can be esti-
mated for different cancer sites. Although the often used
5- or 10-year survival rates may adequately reflect
statistical cure rates for cancers with short natural history,
such as pancreatic cancer, this is not the case for many
other cancers. This highlights the need for continued
long-term cancer surveillance, especially for cancers with
long natural histories such as thyroid cancer and early
stage, well-differentiated breast cancer. This study is rele-
vant for public health and cancer control. Whether knowl-
edge of the threshold year will have any impact on
decisions regarding therapy for cancers thought to have a
good prognosis remains to be investigated.
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